Exosome Therapeutics Market by Distribution by Target Indication, Therapeutic Area, Type of Formulation, Route of Administration and Geography: Industry Trends and Global Forecasts, Industry Trends and Global Forecasts, 2022-2035

In recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse target indication, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Currently, both industry and non-industry players are attempting to develop exosome-based therapeutics for disease management, some of which are already in clinical trials. Moreover, post the onset of the COVID-19 pandemic, there has been a steady increase in the investigational new drug (IND) applications filed for exosome therapies. In a recent review of more than 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use, the exosomes demonstrated benefits in more than 70% of studies.

Q1. What is the current market landscape and recent trends in the exosome therapeutics domain?

The exosome therapeutics market is presently growing at a significant pace among the dynamic sectors of pharmaceutical industry. At present, the pipeline features close to 120 therapeutic candidates, and this number is anticipated to grow further in the foreseen future. More than 40% of the total number of drugs are in clinical stage of development. Further, around 30% of the exosome therapeutics are being developed against oncological indications. It is also worth highlighting that, in the last five years, capital investments worth around USD 500 million have been made by strategic investors for the research and development of exosome therapeutics. Additionally, over time, more than 60 pharmaceutical companies and academic / research institutes have undertaken various initiatives to develop effective exosome therapies against multiple target indications. Of the total candidates, seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute), SF-MSC-EX (Osmangazi University), are currently being evaluated in the advanced clinical stages of development. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the efforts in research and development of various pipeline candidates, over the past decade.

Q3. What are the key challenges faced in the exosome therapeutics domain?

Despite the numerous benefits offered by exosome therapies, developers often face concerns related to the weak therapy preparations, bacterial infections, and contamination with non-exosomal components. Additionally, the heterogeneous nature of such extracellular vesicles (Evs) is one of the major challenges faced during the quantification and characterization of the required Evs from a diverse population of cells. In order to mitigate the aforementioned challenges, novel technologies are being adopted by several stakeholders.

Q4. What are the key value drivers in the exosome therapeutics market?

The factors contributing to the growth of exosome therapeutics market include increasing disease burden, rise in research and development activities for exosome therapeutics, and government funding for the production of such therapeutics. Moreover, the growth potential in the emerging economies bolsters the exosome therapeutics market growth.

Q6. How is the revenue generation potential, associated with exosome therapeutics market likely to evolve in the coming years?

The exosome therapeutics market is projected to grow at a CAGR of more than 30%, with anticipated release of a number of therapies in the foreseen future. In terms of route of administration, the market is likely to be driven by exosome therapeutics designed for intravenous administration. Further, in terms of therapeutic area, majority share of the revenues is expected to be generated by infectious diseases. Specifically, in terms of geography, the exosome therapeutics market in North America is likely to grow at a significant pace, in the long term.

Q7. Who are the key players engaged in the exosome therapeutics market?

The key players engaged in this domain (which have also been capture in this report) include Cellular Biomedicine Group, Codiak BioSciences, Coya Therapeutics, Curexsys, EV Therapeutics, Evox Therapeutics, ExoCoBio, ILIAS Biologics, Rion and SHIFTBIO.

SCOPE OF THE REPORT

The "Exosome Therapeutics Market by Distribution by Target Indication (COVID-19 Disease, Degenerative Meniscal Injury and Retinitis Pigmentosa), Therapeutic Area (Infectious Diseases, Musculoskeletal Disorders and Ophthalmic Diseases), Type of Formulation (Liquid and Aerosol), Route of Administration (Inhalation, Intravenous, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, Industry Trends and Global Forecasts, 2022-2035" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the exosome therapies in the treatment of various diseases. The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the report includes:

General introduction to exosomes, types of extracellular vesicles and their origin, secretion, and type of membrane. In addition, it provides information on the development process of exosomes and details on applications of exosomes, mechanism of different therapies, along with the advantages, risks associated with exosome therapeutics and the future perspectives.

A detailed assessment of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), technology platform (DeliverEXTM platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technology and others), type of payload (protein, biologics, RNA, vaccine, antisense oligonucleotide, DNA / protein and AAV capsids), target disease indication (s) (COVID-19, acute respiratory distress syndrome, skin regeneration, cancer and others), therapeutic area (oncological disorders, dermatological disorders, neurological disorders, infectious diseases, rare disorders, autoimmune disorders and respiratory disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of exosome therapeutics, along with information on their year of establishment, company size and location of headquarters.

Elaborate profiles of the key players engaged in the development of exosome therapeutics, with maximum number of therapeutic programs in their pipeline. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.

Elaborate drug profiles of the key therapeutics in the highest phase of development. Each profile features a brief information on product portfolio and clinical trial information including study title, study detail, status of trial, phase of development, trial location, patient enrollment, study start and end date.

A detailed analysis of completed and ongoing clinical trials of various exosome therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, and number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age group of the patients enrolled, active industry and non-industry players and location of the trials.

An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, during the period, 2017-2022, based on several parameters, such as year of grant awarded, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded).

A detailed analysis of the global events attended by the exosome therapy developers, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participants, and active speakers (in terms of number of events).

An analysis of the partnerships that have been established in this domain since 2017, covering instances of research agreement, licensing agreement, manufacturing agreement, product development and commercialization agreement, merger / acquisition, and other relevant deals.

A detailed analysis of the various investments made since 2017, including grant / award, seed financing, venture capital financing, IPOs, secondary offering, debt financing, other equity, in companies focused on the development of exosome therapeutics.

An analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as pipeline strength, pipeline maturity, financial support, number of investors, partnership activity and start-up health indexing.

A case study highlighting the companies engaged in offering exosome development and manufacturing services along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).

An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, target disease indication(s), route of administration and type of sponsor.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with exosome therapies market in the mid to long term. Based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2027-2035. Our year wise projections of the current and forecasted opportunity within the exosome therapies market have further been segmented across target disease indication(s) (COVID-19, degenerative meniscal injury and retinitis pigmentosa), therapeutic area (infectious diseases, ophthalmic diseases and musculoskeletal disorders), route of administration (intravenous, intra-ocular, intra-articular and inhalation), type of formulation (liquid and aerosol), geography (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

Xavier Avat (Chief Business Officer, Capricor Therapeutics)

Patricia C. Freire (R&D and Innovation Manager, Exogenus Therapeutics)

Soonho Song (Chief Business Officer, ILIAS Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Who are the leading industry and non-industry players engaged in the development of exosome therapies?

Which are the key drugs being developed across early and late stages of development?

What are the key agenda items being discussed in various global events / conferences related to exosomes?

What kind of partnership models are commonly adopted by industry stakeholders?

Which are the leading funding institutes / centers supporting the research related to exosome therapies?

Which geographies are the most active in conducting clinical trials related to exosome therapies?

How is the current and future market opportunity, related to exosome therapies likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of exosome therapeutics market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to exosomes, types of extracellular vesicles and their origin, secretion, and type of membrane. In addition, the chapter provides information on the development process of exosomes. Further, the chapter presents details on applications of exosomes, mechanism of different therapies, along with the advantages, risks associated with exosome therapeutics and the future perspectives.

Chapter 4 provides an overview of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), technology platform (DeliverEXTM platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technology and others), type of payload (protein, biologics, RNA, vaccine, antisense oligonucleotide, DNA / protein and AAV capsids), target disease indication(s) (COVID-19, acute respiratory distress syndrome, skin regeneration, cancer and others), therapeutic area (oncological disorders, dermatological disorders, neurological disorders, infectious disorders, rare disorders, autoimmune disorders and respiratory disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, the chapter provides details on the companies engaged in the development of exosome therapeutics, along with information on their year of establishment, company size and location of headquarters.

Chapter 5 includes detailed profiles of the key players engaged in the development of exosome therapeutics, with maximum number of therapeutic programs in their pipeline. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.

Chapter 6 includes detailed drug profiles of the key therapeutics in the highest phase of development. Each profile features a brief information on product portfolio and clinical trial information including study title, study detail, status of trial, phase of development, trial location, patient enrollment, study start and end date.

Chapter 7 provides information on completed and ongoing clinical trials of various exosome therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age category of the patients enrolled, active industry and non-industry players and location of the trials.

Chapter 8 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, during the period, 2017-2022, based on several parameters, such as year of grant awarded, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded).

Chapter 9 features an analysis of the global events attended by the participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events).

Chapter 10 features an analysis of the partnerships that have been established in this domain since 2017, covering instances of research agreement, licensing agreement, manufacturing agreement, product development and commercialization agreement, merger / acquisition, and other relevant type of deals.

Chapter 11 presents a review of the funding and investments in this domain since 2017, including grant / award, seed financing, venture capital financing, IPOs, secondary offering, debt financing, other equity, in the companies focused on the development of exosome therapeutics.

Chapter 12 presents an analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as pipeline strength, pipeline maturity, financial support, number of investors, partnership activity and start-up health indexing.

Chapter 13 includes information on more than 45 exosome service providers that are currently offering services related to development and manufacturing exosomes, and a detailed analysis based on several parameters, such as types of service(s) offered, method of isolation, method of purification, method of characterization, method of exosome manufacturing, scale of operation and scalability. In addition, it provides details on the companies along with information on their year of establishment, company size and location of headquarters.

Chapter 14 provides a detailed analysis focused on exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, target disease indication(s), route of administration and type of sponsor

Chapter 15 presents an insightful market forecast analysis, highlighting the likely growth of exosome therapeutics market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across target disease indications (COVID-19 Disease, degenerative meniscal injury and retinitis pigmentosa), therapeutic areas (infectious diseases, musculoskeletal disorders and ophthalmic diseases), routes of administration (inhalation, intravenous, intra-articular and intra-ocular), types of formulations (liquid and aerosol), and geography (North America, Europe and Asia-Pacific and Rest of the World).

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented details of interviews held with (in alphabetical order of company / organization names) Xavier Avat (Chief Business Officer, Capricor Therapeutics), Patricia C. Freire (R&D and Innovation Manager, Exogenus Therapeutics) and Soonho Song (Chief Business Officer, ILIAS Biologics)

Chapter 17 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

Product Code: RA100394

1. PREFACE

1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Exosomes
- 3.1.1. Types of Extracellular Vesicles
- 3.1.1. Potential Sources of Exosomes
3.2. Exosome Biogenesis
- 3.2.1. Exosome Formation and Development Process
- 3.2.2. Secretion of Exosomes
3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
- 3.4.1. Exosome Drug Therapy
- 3.4.2. Exosome RNAi Therapy
- 3.4.3. Exosome Immunotherapy
3.5. Advantages of Exosome Therapies
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics

4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE

4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Technology Platform
- 4.2.3. Analysis by Type of Payload
- 4.2.4. Analysis by Type of Formulation
- 4.2.5. Analysis by Type of Therapy
- 4.2.6. Analysis by Derived Source
- 4.2.7. Analysis by Target Disease Indication(s)
- 4.2.8. Analysis by Therapeutic Area
- 4.2.9. Analysis by Phase of Development and Therapeutic Area
- 4.2.10. Analysis by Route of Administration
- 4.2.11. Analysis by Therapeutic Area and Route of Administration
- 4.2.12. Analysis by Type of Therapy (By Method of Composition)
- 4.2.13. Analysis by Line of Treatment
- 4.2.14. Analysis by Dosing Frequency
4.3. Exosome Therapeutics Developers
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters
- 4.3.4. Most Active Players: Analysis by Number of Therapeutics

5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES

5.1. Codiak BioSciences
- 5.1.1. Company Overview
- 5.1.2. Product Portfolio
- 5.1.3. Clinical Trial Information
- 5.1.4. Recent Developments and Future Outlook
5.2. Coya Therapeutics
- 5.2.1. Company Overview
- 5.2.2. Product Portfolio
- 5.2.3. Recent Developments and Future Outlook
5.3. Curexsys
- 5.3.1. Company Overview
- 5.3.2. Product Portfolio
- 5.3.3. Recent Developments and Future Outlook
5.4. EV Therapeutics
- 5.4.1. Company Overview
- 5.4.2. Product Portfolio
- 5.4.3. Recent Developments and Future Outlook
5.5. Evox Therapeutics
- 5.5.1. Company Overview
- 5.5.2. Product Portfolio
- 5.5.3. Recent Developments and Future Outlook
5.6. SHIFTBIO
- 5.6.1. Company Overview
- 5.6.2. Product Portfolio
- 5.6.3. Recent Developments and Future Outlook

6. EXOSOME THERAPEUTICS: DRUG PROFILES

6.1. AEGLE Therapeutics
- 6.1.1. Company Overview
- 6.1.2. AGLE-102: Product Portfolio
  - 6.1.2.1. AGLE-102: Clinical Trial Information
- 6.1.3. Recent Developments and Future Outlook
6.2. AVEM Healthcare
- 6.2.1. Company Overview
- 6.2.2. Ardoxso: Product Portfolio
  - 6.2.2.1. Ardoxso: Clinical Trial Information
- 6.2.3. Recent Developments and Future Outlook
6.3. Cellular Biomedicine Group
- 6.3.1. Company Overview
- 6.3.2. Financial Information
- 6.3.3. haMPC-Exos: Product Portfolio
  - 6.3.3.1. haMPC-Exos: Clinical Trial Information
- 6.3.4. hMSC-Exos: Product Portfolio
  - 6.3.4.1. hMSC-Exos: Clinical Trial Information
- 6.3.5. Undisclosed Drug 1: Product Portfolio
  - 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
- 6.3.6. Recent Developments and Future Outlook
6.4. OBCTCD24
- 6.4.1. Company Overview
- 6.4.2. CovenD24: Product Portfolio
  - 6.4.2.1. CovenD24: Clinical Trial Information
- 6.4.3. Recent Developments and Future Outlook
6.5. ReNeuron
- 6.5.1. Company Overview
- 6.5.2. Financial Information
- 6.5.3. Undisclosed Drug 1: Product Portfolio
  - 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
- 6.5.4. Recent Developments and Future Outlook
6.6. Stem Cell Medicine
- 6.6.1. Company Overview
- 6.6.2. Undisclosed Drug 1: Product Portfolio
- 6.6.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
- 7.2.1. Analysis by Trial Status
- 7.2.2. Analysis by Trial Registration Year
- 7.2.3. Analysis by Type of Sponsor / Collaborator
- 7.2.4. Analysis by Registration Year and Type of Study
- 7.2.5. Analysis by Registration Year and Status of Trial
- 7.2.6. Analysis by Study Design
- 7.2.7. Analysis by Patient Enrollment
- 7.2.8. Year-wise Trend of Completed and Recruiting Trials
- 7.2.9. Analysis by Age Category
- 7.2.10. Analysis by Phase of Development and Trial Status
- 7.2.11. Analysis by Phase of Development and Patient Enrollment
- 7.2.12. Most Active Industry Players: Analysis by Number of Registered Trials
- 7.2.13. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 7.2.14. Analysis by Trial Location
- 7.2.15. Analysis by Trial Status and Geography

8. ACADEMIC GRANT ANALYSIS

8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded
8.5. Popular NIH Departments: Analysis by Number of Grants
8.6. Analysis by Type of Funding Institute Center
8.7. Analysis by Support Period
8.8. Analysis by Purpose of Grants
8.9. Word Cloud Analysis: Emerging Focus Area
8.10. Analysis by Grant Activity Code
8.11. Analysis by Local Recipients
8.12. Analysis by Type of Recipient Organization
8.13. Popular Recipient Organizations: Analysis by Amount Awarded
8.14. Popular Recipient Organizations: Analysis by Number of Grants
8.15. Analysis by Study Section Involved
8.16. Analysis by Type of Grant Application
8.17. Analysis by Funding Institute Center and Support Year

9. GLOBAL EVENT ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
- 9.3.1. Analysis by Year of Event
- 9.3.2. Analysis by Event Platform
- 9.3.3. Analysis by Type of Event
- 9.3.4. Analysis by Location of Event
- 9.3.5. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
- 9.3.6. Most Active Organizers: Analysis by Number of Events
- 9.3.7. Most Active Industry Participants: Analysis by Number of Events
- 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
- 9.3.9. Analysis by Designation of Participant
- 9.3.10. Analysis by Affiliated Department of Participant
- 9.3.11. Most Active Speakers: Analysis by Number of Events

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Year and Type of Partnership
- 10.3.4. Analysis by Company and Type of Partnership
- 10.3.5. Analysis by Type of Technology Platform
- 10.3.6. Analysis by Type of Partner
- 10.3.7. Word Cloud Analysis: Emerging Focus Areas
- 10.3.8. Analysis by Target Disease Indication(s)
- 10.3.9. Analysis by Therapeutic Area
- 10.3.10. Analysis by Therapeutic Area and Type of Partnership
- 10.3.11. Most Active Players: Analysis by Number of Partnerships
- 10.3.12. Regional Analysis
- 10.3.13. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Year, Type of Funding and Amount Invested
11.9. Analysis by Purpose of Funding
11.10. Analysis by Target Disease Indication(s)
11.11. Analysis by Therapeutic Area
11.12. Most Active Players: Analysis by Number of Funding Instances
11.13. Most Active Players: Analysis by Amount Invested
11.14. Key Investors: Analysis by Number of Funding Instances
11.15. Regional Analysis
11.16. Summary of Funding Instances

12. START-UP HEALTH INDEXING

12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Maturity
12.3. Analysis by Pipeline Strength
12.4. Analysis by Financial Support
12.5. Analysis by Number of Investors
12.6. Analysis by Partnership Activity
12.7. Start-up Health Indexing: Roots Analysis Perspective

13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Service Providers Landscape
- 13.2.1. Analysis by Year of Establishment
- 13.2.2. Analysis by Company Size
- 13.2.3. Analysis by Location of Headquarters
- 13.2.4. Analysis by Location of Headquarters and Company Size
13.3. Analysis by Type of Service(s) Offered
- 13.3.1. Analysis by Method of Isolation
- 13.3.2. Analysis by Method of Purification
- 13.3.3. Analysis by Method of Characterization
- 13.3.4. Analysis by Method of Exosome Manufacturing
- 13.3.5. Analysis by Scale of Operation
- 13.3.6. Analysis by Scalability

14. DRUG FAILURE ANALYSIS

14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
- 14.2.1. Analysis by Study Start Year and Year of Termination of the Clinical Trials
- 14.2.2. Analysis by Trial Status of Discontinuation
- 14.2.3. Analysis by Target Disease Indication(s)
- 14.2.4. Analysis by Route of Administration
- 14.2.5. Analysis by Type of Sponsor
- 14.2.6. Analysis by Reasons for Drug Failure
- 14.2.7. Word Cloud Analysis: Emerging Focus Area

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

15.1. Forecast Methodology and Key Assumptions
15.1. Global Exosome Therapeutics Market, 2027-2035
15.2. Global Exosome Therapeutics Market, 2027-2035: Distribution by Target Disease Indication(s)
- 15.2.1. Exosome Therapeutics Market for COVID-19, 2027-2035
- 15.2.2. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2027-2035
- 15.2.3. Exosome Therapeutics Market for Retinitis Pigmentosa, 2027-2035
15.3. Global Exosome Therapeutics Market, 2027-2035: Distribution by Therapeutic Area
- 15.3.1. Exosome Therapeutics Market for Infectious Diseases, 2027-2035
- 15.3.2. Exosome Therapeutics Market for Ophthalmic Diseases, 2027-2035
- 15.3.3. Exosome Therapeutics Market for Musculoskeletal Disorders, 2027-2035
15.4. Global Exosome Therapeutics Market, 2027-2035: Distribution by Route of Administration
- 15.4.1. Intravenous Exosome Therapeutics Market, 2027-2035
- 15.4.2. Intra-ocular Exosome Therapeutics Market, 2027-2035
- 15.4.3. Intra-articular Exosome Therapeutics Market, 2027-2035
- 15.4.4. Inhalation Exosome Therapeutics Market, 2027-2035
15.5. Global Exosome Therapeutics Market, 2027-2035: Distribution by Type of Formulation
- 15.5.1. Exosome Therapeutics Market for Liquid Formulations, 2027-2035
- 15.5.2. Exosome Therapeutics Market for Aerosol Formulations, 2027-2035
15.6. Global Exosome Therapeutics Market, 2027-2035: Distribution by Geography
- 15.6.1. Exosome Therapeutics Market in North America, 2029-2035
- 15.6.2. Exosome Therapeutics Market in Europe, 2027-2035
- 15.6.3. Exosome Therapeutics Market in Asia Pacific, 2030-2035
15.7. Attractiveness and Competitiveness Matrix

16. EXECUTIVE INSIGHTS

16.1. Capricor Therapeutics
- 16.1.1. Company Snapshot
- 16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer
16.2. Exogenus Therapeutics
- 16.2.1. Company Snapshot
- 16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager
16.3. ILIAS Biologics
- 16.3.1. Company Snapshot
- 16.3.2. Interview Transcript: Soonho Song, Chief Business Officer

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS